Artificial Intelligence, Machine Learning, and Cardiovascular Disease

The Role of Artificial Intelligence in Providing Real-Time Guidance During Interventional Cardiology Procedures: A Narrative Review

Integrating artificial intelligence (AI) in interventional cardiology revolutionizes procedural guidance, particularly in high-stakes environments such as angioplasty and stent placement. In this narrative review we explore the role of AI in providing real-time decision support, enhancing precision, and improving patient outcomes during these complex procedures. AI algorithms can identify critical anatomical features, predict complications, and optimize stent positioning with unprecedented accuracy by analyzing data from imaging modalities like intravascular ultrasound and optical coherence tomography. The findings of this narrative review, from which we have reviewed more than 150 studies across multiple databases, highlight the necessity of continued research and development to utilize AI to its full potential in enhancing the efficacy and safety of interventional procedures. In this review we highlight AI's current advancements, challenges, and potential in real-time interventional cardiology procedures, emphasizing its transformative impact on clinical practice and patient care.

Volatilome and machine learning in ischemic heart disease: Current challenges and future perspectives

Integrating exhaled breath analysis into the diagnosis of cardiovascular diseases holds significant promise as a valuable tool for future clinical use, particularly for ischemic heart disease (IHD). However, current research on the volatilome (exhaled breath composition) in heart disease remains underexplored and lacks sufficient evidence to confirm its clinical validity. Key challenges hindering the application of breath analysis in diagnosing IHD include the scarcity of studies (only three published papers to date), substantial methodological bias in two of these studies, and the absence of standardized protocols for clinical implementation. Additionally, inconsistencies in methodologies-such as sample collection, analytical techniques, machine learning (ML) approaches, and result interpretation-vary widely across studies, further complicating their reproducibility and comparability. To address these gaps, there is an urgent need to establish unified guidelines that define best practices for breath sample collection, data analysis, ML integration, and biomarker annotation. Until these challenges are systematically resolved, the widespread adoption of exhaled breath analysis as a reliable diagnostic tool for IHD remains a distant goal rather than an imminent reality.

Environmental Factors and Cardiovascular Susceptibility: Toward Personalized Prevention Mediated by the Role of Artificial Intelligence-A Narrative Review

Background and Purpose

Cardiovascular diseases (CVD) represent a significant global health challenge due to high morbidity and mortality rates, that necessitate approaching the intricate relation between cardiovascular susceptibility and environmental factors, highlighting the importance of creating personalized cardiovascular prevention plans. Furthermore, as it is becoming integrated with the various aspects of healthcare, the role of artificial intelligence in cardiovascular and precision medicine is driving innovations towards personalized care. This review dives into the complex connection between cardiovascular susceptibility and environmental risk highlighting the importance of creating personalized cardiovascular preventive strategies in light of the upcoming artificial intelligence.

Methods

An in-depth review was conducted using PubMed and ScienceDirect, to collect data from all articles that handled environmental factors and cardiovascular susceptibility with special emphasis on the up-to-date emerging role of artificial intelligence in preventive strategies.

Results

The review revealed high heritability estimates and highlighted the significance of modifiable risk factors which are pivotal determinants affecting CVD susceptibility. The integration of artificial intelligence is implementing the power of precision preventive medicine that can be directed toward specific environmental factors, shifting the whole healthcare system to superior outcomes.

Conclusion

Recognizing the preventability of CVD through personalized environmental modifications, this review advocates tailored prevention plans that account for individual characteristics. Despite its proven efficacy in managing modifiable risk factors, achieving optimal cardiovascular health remains challenging, necessitating innovative strategies and the integration of artificial intelligence in personalized healthcare.

Detecting severe coronary artery stenosis in T2DM patients with NAFLD using cardiac fat radiomics-based machine learning

To analyze radiomics features of cardiac adipose tissue in individuals with type 2 diabetes (T2DM) and non-alcoholic fatty liver disease (NAFLD), integrating relevant clinical indicators, and employing machine learning techniques to construct a precise model for detecting severe coronary artery stenosis. A retrospective analysis of 710 T2DM patients with NAFLD was conducted at First People's Hospital of Wenling. The study population was randomly divided into a training set (n = 497) and a validation set (n = 213). Radiomics features from cardiac fat CT images, including epicardial adipose tissue (EAT) and paracardial adipose tissue (PAT), were extracted for all patients. The semi-automated segmentation and extraction of shape, first-order statistics, texture, and wavelet were performed using specialized software. Simultaneously, clinical characteristics were collected. Following feature selection, four machine learning algorithms were utilized to develop radiomics, clinical, and combined radiomics-clinical models. The detection performance of these models was subsequently evaluated in both the training and validation cohorts. Additionally, Shapley Additive exPlanations (SHAP) values were calculated to quantify the importance of features. A total of 10 radiomics features for EAT and PAT were extracted from CT images after feature selection. The clinical model obtained an area under the curve (AUC) of 0.747 with the support vector machine (SVM), while the radiomics model reached an AUC of 0.838 with the extreme gradient boosting (XGBoost) algorithm. In comparison, the radiomics-clinical model using XGBoost demonstrated superior detection capability, achieving an AUC of 0.883 in the training set and maintaining high performance in the validation set, with the highest F1 score, accuracy, and precision. SHAP analysis revealed the importance of radiomics features from EAT and PAT, as well as clinical factors such as diabetes duration, global longitudinal strain (GLS), and low-density lipoprotein cholesterol (LDL-C), in detecting severe coronary artery stenosis. This study confirms that the integrated application of cardiac fat radiomics features and clinical data using machine learning models, particularly the XGBoost algorithm, facilitates the detection of severe coronary artery stenosis in T2DM patients with NAFLD. SHAP analysis further elucidates the contribution of key variables in the model, providing crucial foundations for personalized treatment decision-making.

The Heart of Transformation: Exploring Artificial Intelligence in Cardiovascular Disease

The application of artificial intelligence (AI) and machine learning (ML) in medicine and healthcare has been extensively explored across various areas. AI and ML can revolutionize cardiovascular disease management by significantly enhancing diagnostic accuracy, disease prediction, workflow optimization, and resource utilization. This review summarizes current advancements in AI and ML concerning cardiovascular disease, including their clinical investigation and use in primary cardiac imaging techniques, common cardiovascular disease categories, clinical research, patient care, and outcome prediction. We analyze and discuss commonly used AI and ML models, algorithms, and methodologies, highlighting their roles in improving clinical outcomes while addressing current limitations and future clinical applications. Furthermore, this review emphasizes the transformative potential of AI and ML in cardiovascular practice by improving clinical decision making, reducing human error, enhancing patient monitoring and support, and creating more efficient healthcare workflows for complex cardiovascular conditions.

Artificial intelligence for personalized nanomedicine; from material selection to patient outcomes

INTRODUCTION

Artificial intelligence (AI) is changing the field of nanomedicine by exploring novel nanomaterials for developing therapies of high efficacy. AI works on larger datasets, finding sought-after nano-properties for different therapeutic aims and eventually enhancing nanomaterials' safety and effectiveness. AI leverages patient clinical and genetic data to predict outcomes, guide treatments, and optimize drug dosages and forms, enhancing benefits while minimizing side effects. AI-supported nanomedicine faces challenges like data fusion, ethics, and regulation, requiring better tools and interdisciplinary collaboration. This review highlights the importance of AI regarding patient care and urges scientists, medical professionals, and regulators to adopt AI for better outcomes.

AREAS COVERED

Personalized Nanomedicine, Material Discovery, AI-Driven Therapeutics, Data Integration, Drug Delivery, Patient Centric Care.

EXPERT OPINION

Today, AI can improve personalized health wellness through the discovery of new types of drug nanocarriers, nanomedicine of specific properties to tackle targeted medical needs, and an increment in efficacy along with safety. Nevertheless, problems such as ethical issues, data security, or unbalanced data sets need to be addressed. Potential future developments involve using AI and quantum computing together and exploring telemedicine i.e. the Internet-of-Medical-Things (IoMT) approach can enhance the quality of patient care in a personalized manner by timely decision-making.

The molecular mechanisms of cardiac development and related diseases

Cardiac development is a complex and intricate process involving numerous molecular signals and pathways. Researchers have explored cardiac development through a long journey, starting with early studies observing morphological changes and progressing to the exploration of molecular mechanisms using various molecular biology methods. Currently, advancements in stem cell technology and sequencing technology, such as the generation of human pluripotent stem cells and cardiac organoids, multi-omics sequencing, and artificial intelligence (AI) technology, have enabled researchers to understand the molecular mechanisms of cardiac development better. Many molecular signals regulate cardiac development, including various growth and transcription factors and signaling pathways, such as WNT signaling, retinoic acid signaling, and Notch signaling pathways. In addition, cilia, the extracellular matrix, epigenetic modifications, and hypoxia conditions also play important roles in cardiac development. These factors play crucial roles at one or even multiple stages of cardiac development. Recent studies have also identified roles for autophagy, metabolic transition, and macrophages in cardiac development. Deficiencies or abnormal expression of these factors can lead to various types of cardiac development abnormalities. Nowadays, congenital heart disease (CHD) management requires lifelong care, primarily involving surgical and pharmacological treatments. Advances in surgical techniques and the development of clinical genetic testing have enabled earlier diagnosis and treatment of CHD. However, these technologies still have significant limitations. The development of new technologies, such as sequencing and AI technologies, will help us better understand the molecular mechanisms of cardiac development and promote earlier prevention and treatment of CHD in the future.

Comprehensive Analysis of Cardiovascular Diseases: Symptoms, Diagnosis, and AI Innovations

Cardiovascular diseases are some of the underlying reasons contributing to the relentless rise in mortality rates across the globe. In this regard, there is a genuine need to integrate advanced technologies into the medical realm to detect such diseases accurately. Moreover, numerous academic studies have been published using AI-based methodologies because of their enhanced accuracy in detecting heart conditions. This research extensively delineates the different heart conditions, e.g., coronary artery disease, arrhythmia, atherosclerosis, mitral valve prolapse/mitral regurgitation, and myocardial infarction, and their underlying reasons and symptoms and subsequently introduces AI-based detection methodologies for precisely classifying such diseases. The review shows that the incorporation of artificial intelligence in detecting heart diseases exhibits enhanced accuracies along with a plethora of other benefits, like improved diagnostic accuracy, early detection and prevention, reduction in diagnostic errors, faster diagnosis, personalized treatment schedules, optimized monitoring and predictive analysis, improved efficiency, and scalability. Furthermore, the review also indicates the conspicuous disparities between the results generated by previous algorithms and the latest ones, paving the way for medical researchers to ascertain the accuracy of these results through comparative analysis with the practical conditions of patients. In conclusion, AI in heart disease detection holds paramount significance and transformative potential to greatly enhance patient outcomes, mitigate healthcare expenditure, and amplify the speed of diagnosis.

Managing Dyslipidemia in Children: Current Approaches and the Potential of Artificial Intelligence

Dyslipidemia is abnormal lipid and lipoprotein levels in the blood, influenced mainly by genetics, lifestyle, and environmental factors. The management of lipid levels in children involves early screening, nonpharmacological interventions such as lifestyle modifications and dietary changes, nutraceuticals, and pharmacological treatments, including drug therapy. However, the prevalence of dyslipidemia in the pediatric population is increasing, particularly among obese children, which is a significant risk factor for cardiovascular complications. This narrative review analyzes current literature on the management of dyslipidemia in children and explores the potential of artificial intelligence (AI) to improve screening, diagnosis, and treatment outcomes. A comprehensive literature search was conducted using Google Scholar and PubMed databases, focusing primarily on the application of AI in managing dyslipidemia. AI has been beneficial in managing lipid disorders, including lipid profile analysis, obesity assessments, and familial hypercholesterolemia screening. Deep learning models, machine learning algorithms, and artificial neural networks have improved diagnostic accuracy and treatment efficacy. While most studies are done in the adult population, the promising results suggest further exploring AI management of dyslipidemia in children.

Yasin J, Hanifa H, Sabet CJ, Dinh NH, Harky A, Jain J, Jain H. Presurgery and postsurgery: advancements in artificial intelligence and machine learning models for enhancing patient management in infective endocarditis

Infective endocarditis (IE) is a severe infection of the inner lining of the heart, known as the endocardium. It is characterized by a range of symptoms and has a complicated pattern of occurrence, leading to a significant number of deaths. IE poses significant diagnostic and treatment difficulties. This evaluation examines the utilization of artificial intelligence (AI) and machine learning (ML) models in addressing IE management. It focuses on the most recent advancements and possible applications. Through this paper, the authors observe that AI/ML can significantly enhance and outperform traditional diagnostic methods leading to more accurate risk stratification, personalized therapies, as well and real-time monitoring facilities. For example, early postsurgical mortality prediction models like SYSUPMIE achieved 'very good' area under the curve (AUROC) values exceeding 0.81. Additionally, AI/ML has improved diagnostic accuracy for prosthetic valve endocarditis, with PET-ML models increasing sensitivity from 59 to 72% when integrated into ESC criteria and reaching a high specificity of 83%. Furthermore, inflammatory biomarkers such as IL-15 and CCL4 have been identified as predictive markers, showing 91% accuracy in forecasting mortality, and identifying high-risk patients with specific CRP, IL-15, and CCL4 levels. Even simpler ML models, like Naïve Bayes, demonstrated an excellent accuracy of 92.30% in death rate prediction following valvular surgery for IE patients. Furthermore, this review provides a vital assessment of the advantages and disadvantages of such AI/ML models, such as better-quality decision support approaches like adaptive response systems on one hand, and data privacy threats or ethical concerns on the other hand. In conclusion, Al and ML must continue, through multicentric and validated research, to advance cardiovascular medicine, and overcome implementation challenges to boost patient outcomes and healthcare delivery.

A Comprehensive Review on Potential In Silico Screened Herbal Bioactive Compounds and Host Targets in the Cardiovascular Disease Therapy

Herbal medicines (HMs) have deciphered indispensable therapeutic effects against cardiovascular disease (CVD) (the predominant cause of death worldwide). The conventional CVD therapy approaches have not been efficient and need alternative medicines. The objective of this study was a review of herbal bioactive compound efficacy for CVD therapy based on computational and in silico studies. HM bioactive compounds with potential anti-CVD traits include campesterol, naringenin, quercetin, stigmasterol, tanshinaldehyde, Bryophyllin A, Bryophyllin B, beta-sitosterol, punicalagin, butein, eriodyctiol, butin, luteolin, and kaempferol discovered using computational studies. Some of the bioactive compounds have exhibited therapeutic effects, as followed by in vitro (tanshinaldehyde, punicalagin, butein, eriodyctiol, and butin), in vivo (gallogen, luteolin, chebulic acid, butein, eriodyctiol, and butin), and clinical trials (quercetin, campesterol, and naringenin). The main mechanisms of action of bioactive compounds for CVD healing include cell signaling and inhibition of inflammation and oxidative stress, decrease of lipid accumulation, and regulation of metabolism and immune cells. Further experimental studies are required to verify the anti-CVD effects of herbal bioactive compounds and their pharmacokinetic/pharmacodynamic features.

The Role of Artificial Intelligence and Machine Learning in Cardiovascular Imaging and Diagnosis: Current Insights and Future Directions

Cardiovascular diseases (CVDs) are the major cause of mortality worldwide, emphasizing the critical need for timely and accurate diagnosis. Artificial intelligence (AI) and machine learning (ML) have become revolutionary tools in the healthcare system with significant potential for cardiovascular diagnosis and imaging. AI and ML techniques, including supervised and unsupervised learning, logistic regression, deep learning models, neural networks, and convolutional neural networks (CNNs), have significantly advanced cardiovascular imaging. Applications in echocardiography include left and right ventricular segmentation, ejection fraction measurement, and wall motion analysis. AI and ML hold substantial promise for revolutionizing cardiovascular imaging, demonstrating improvements in diagnostic accuracy and efficiency. This narrative review aims to explore the current applications, advantages, challenges, and future pathways of AI and ML in cardiovascular imaging, highlighting their impact on different imaging modalities and their integration into clinical practice.

Leveraging Artificial Intelligence to Optimize the Care of Peripheral Artery Disease Patients

Peripheral artery disease is a major atherosclerotic disease that is associated with poor outcomes such as limb loss, cardiovascular morbidity, and death. Artificial intelligence (AI) has seen increasing integration in medicine, and its various applications can optimize the care of peripheral artery disease (PAD) patients in diagnosis, predicting patient outcomes, and imaging interpretation. In this review, we introduce various AI applications such as natural language processing, supervised machine learning, and deep learning, and we analyze the current literature in which these algorithms have been applied to PAD.

Construction of machine learning diagnostic models for cardiovascular pan-disease based on blood routine and biochemical detection data

BACKGROUND

Cardiovascular disease, also known as circulation system disease, remains the leading cause of morbidity and mortality worldwide. Traditional methods for diagnosing cardiovascular disease are often expensive and time-consuming. So the purpose of this study is to construct machine learning models for the diagnosis of cardiovascular diseases using easily accessible blood routine and biochemical detection data and explore the unique hematologic features of cardiovascular diseases, including some metabolic indicators.

METHODS

After the data preprocessing, 25,794 healthy people and 32,822 circulation system disease patients with the blood routine and biochemical detection data were utilized for our study. We selected logistic regression, random forest, support vector machine, eXtreme Gradient Boosting (XGBoost), and deep neural network to construct models. Finally, the SHAP algorithm was used to interpret models.

RESULTS

The circulation system disease prediction model constructed by XGBoost possessed the best performance (AUC: 0.9921 (0.9911-0.9930); Acc: 0.9618 (0.9588-0.9645); Sn: 0.9690 (0.9655-0.9723); Sp: 0.9526 (0.9477-0.9572); PPV: 0.9631 (0.9592-0.9668); NPV: 0.9600 (0.9556-0.9644); MCC: 0.9224 (0.9165-0.9279); F1 score: 0.9661 (0.9634-0.9686)). Most models of distinguishing various circulation system diseases also had good performance, the model performance of distinguishing dilated cardiomyopathy from other circulation system diseases was the best (AUC: 0.9267 (0.8663-0.9752)). The model interpretation by the SHAP algorithm indicated features from biochemical detection made major contributions to predicting circulation system disease, such as potassium (K), total protein (TP), albumin (ALB), and indirect bilirubin (NBIL). But for models of distinguishing various circulation system diseases, we found that red blood cell count (RBC), K, direct bilirubin (DBIL), and glucose (GLU) were the top 4 features subdividing various circulation system diseases.

CONCLUSIONS

The present study constructed multiple models using 50 features from the blood routine and biochemical detection data for the diagnosis of various circulation system diseases. At the same time, the unique hematologic features of various circulation system diseases, including some metabolic-related indicators, were also explored. This cost-effective work will benefit more people and help diagnose and prevent circulation system diseases.

Intelligent cardiovascular disease diagnosis using deep learning enhanced neural network with ant colony optimization

To identify patterns in big medical datasets and use Deep Learning and Machine Learning (ML) to reliably diagnose Cardio Vascular Disease (CVD), researchers are currently delving deeply into these fields. Training on large datasets and producing highly accurate validation results is exceedingly difficult. Furthermore, early and precise diagnosis is necessary due to the increased global prevalence of cardiovascular disease (CVD). However, the increasing complexity of healthcare datasets makes it challenging to detect feature connections and produce precise predictions. To address these issues, the Intelligent Cardiovascular Disease Diagnosis based on Ant Colony Optimisation with Enhanced Deep Learning (ICVD-ACOEDL) model was developed. This model employs feature selection (FS) and hyperparameter optimization to diagnose CVD. Applying a min-max scaler, medical data is first consistently prepared. The key feature that sets ICVD-ACOEDL apart is the use of Ant Colony Optimisation (ACO) to select an optimal feature subset, which in turn helps to upgrade the performance of the ensuring deep learning enhanced neural network (DLENN) classifier. The model reforms the hyperparameters of DLENN for CVD classification using Bayesian optimization. Comprehensive evaluations on benchmark medical datasets show that ICVD-ACOEDL exceeds existing techniques, indicating that it could have a significant impact on CVD diagnosis. The model furnishes a workable way to increase CVD classification efficiency and accuracy in real-world medical situations by incorporating ACO for feature selection, min-max scaling for data pre-processing, and Bayesian optimization for hyperparameter tweaking.

Trustworthy and ethical AI-enabled cardiovascular care: a rapid review

BACKGROUND

Artificial intelligence (AI) is increasingly used for prevention, diagnosis, monitoring, and treatment of cardiovascular diseases. Despite the potential for AI to improve care, ethical concerns and mistrust in AI-enabled healthcare exist among the public and medical community. Given the rapid and transformative recent growth of AI in cardiovascular care, to inform practice guidelines and regulatory policies that facilitate ethical and trustworthy use of AI in medicine, we conducted a literature review to identify key ethical and trust barriers and facilitators from patients' and healthcare providers' perspectives when using AI in cardiovascular care.

METHODS

In this rapid literature review, we searched six bibliographic databases to identify publications discussing transparency, trust, or ethical concerns (outcomes of interest) associated with AI-based medical devices (interventions of interest) in the context of cardiovascular care from patients', caregivers', or healthcare providers' perspectives. The search was completed on May 24, 2022 and was not limited by date or study design.

RESULTS

After reviewing 7,925 papers from six databases and 3,603 papers identified through citation chasing, 145 articles were included. Key ethical concerns included privacy, security, or confidentiality issues (n = 59, 40.7%); risk of healthcare inequity or disparity (n = 36, 24.8%); risk of patient harm (n = 24, 16.6%); accountability and responsibility concerns (n = 19, 13.1%); problematic informed consent and potential loss of patient autonomy (n = 17, 11.7%); and issues related to data ownership (n = 11, 7.6%). Major trust barriers included data privacy and security concerns, potential risk of patient harm, perceived lack of transparency about AI-enabled medical devices, concerns about AI replacing human aspects of care, concerns about prioritizing profits over patients' interests, and lack of robust evidence related to the accuracy and limitations of AI-based medical devices. Ethical and trust facilitators included ensuring data privacy and data validation, conducting clinical trials in diverse cohorts, providing appropriate training and resources to patients and healthcare providers and improving their engagement in different phases of AI implementation, and establishing further regulatory oversights.

CONCLUSION

This review revealed key ethical concerns and barriers and facilitators of trust in AI-enabled medical devices from patients' and healthcare providers' perspectives. Successful integration of AI into cardiovascular care necessitates implementation of mitigation strategies. These strategies should focus on enhanced regulatory oversight on the use of patient data and promoting transparency around the use of AI in patient care.

Application of Artificial Intelligence in Cardiology: A Bibliometric Analysis

Recent advancements in artificial intelligence (AI) applications in medicine have been significant over the past 30 years. To monitor current research developments, it is crucial to examine the latest trends in AI adoption across various medical fields. This bibliometric analysis focuses on AI applications in cardiology. Unlike existing literature reviews, this study specifically examines journal articles published in the last decade, sourced from both Scopus and Web of Science databases, to illustrate the recent trends in AI within cardiology. The bibliometric analysis involves a statistical and quantitative evaluation of the literature on AI application in cardiovascular medicine over a defined period. A comprehensive global literature review is conducted to identify key research areas, authors, and their interrelationships through published works. The leading institutions and most influential authors in research on the role of AI in cardiology were located in the United States, the United Kingdom, and China. This study also provides researchers with an overview of the evolution of research in AI and cardiology. The main contribution of this study is to highlight the prominent authors, countries, journals, institutions, keywords, and trends in the development of AI in cardiology.

Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy

Cardiovascular diseases (CVDs) are the leading cause of global mortality among non-communicable diseases. Current cardiac regeneration treatments have limitations and may lead to adverse reactions. Hence, innovative technologies are needed to address these shortcomings. Messenger RNA (mRNA) emerges as a promising therapeutic agent due to its versatility in encoding therapeutic proteins and targeting "undruggable" conditions. It offers low toxicity, high transfection efficiency, and controlled protein production without genome insertion or mutagenesis risk. However, mRNA faces challenges such as immunogenicity, instability, and difficulty in cellular entry and endosomal escape, hindering its clinical application. To overcome these hurdles, lipid nanoparticles (LNPs), notably used in COVID-19 vaccines, have a great potential to deliver mRNA therapeutics for CVDs. This review highlights recent progress in mRNA-LNP therapies for CVDs, including Myocardial Infarction (MI), Heart Failure (HF), and hypercholesterolemia. In addition, LNP-mediated mRNA delivery for CAR T-cell therapy and CRISPR/Cas genome editing in CVDs and the related clinical trials are explored. To enhance the efficiency, safety, and clinical translation of mRNA-LNPs, advanced technologies like artificial intelligence (AGILE platform) in RNA structure design, and optimization of LNP formulation could be integrated. We conclude that the strategies to facilitate the extra-hepatic delivery and targeted organ tropism of mRNA-LNPs (SORT, ASSET, SMRT, and barcoded LNPs) hold great prospects to accelerate the development and translation of mRNA-LNPs in CVD treatment.

Pulse wave signal-driven machine learning for identifying left ventricular enlargement in heart failure patients

BACKGROUND

Left ventricular enlargement (LVE) is a common manifestation of cardiac remodeling that is closely associated with cardiac dysfunction, heart failure (HF), and arrhythmias. This study aimed to propose a machine learning (ML)-based strategy to identify LVE in HF patients by means of pulse wave signals.

METHOD

We constructed two high-quality pulse wave datasets comprising a non-LVE group and an LVE group based on the 264 HF patients. Fourier series calculations were employed to determine if significant frequency differences existed between the two datasets, thereby ensuring their validity. Then, the ML-based identification was undertaken by means of classification and regression models: a weighted random forest model was employed for binary classification of the datasets, and a densely connected convolutional network was utilized to directly estimate the left ventricular diastolic diameter index (LVDdI) through regression. Finally, the accuracy of the two models was validated by comparing their results with clinical measurements, using accuracy and the area under the receiver operating characteristic curve (AUC-ROC) to assess their capability for identifying LVE patients.

RESULTS

The classification model exhibited superior performance with an accuracy of 0.91 and an AUC-ROC of 0.93. The regression model achieved an accuracy of 0.88 and an AUC-ROC of 0.89, indicating that both models can quickly and accurately identify LVE in HF patients.

CONCLUSION

The proposed ML methods are verified to achieve effective classification and regression with good performance for identifying LVE in HF patients based on pulse wave signals. This study thus demonstrates the feasibility and potential of the ML-based strategy for clinical practice while offering an effective and robust tool for diagnosing and intervening ventricular remodeling.

Emergence of Artificial Intelligence and Machine Learning Models in Sudden Cardiac Arrest: A Comprehensive Review of Predictive Performance and Clinical Decision Support

Sudden cardiac death/sudden cardiac arrest (SCD/SCA) is an increasingly prevalent cause of mortality globally, particularly in individuals with preexisting cardiac conditions. The ambiguous premortem warnings and the restricted interventional window related to SCD account for the complexity of the condition. Current reports suggest SCD to be accountable for 20% of all deaths hence accurately predicting SCD risk is an imminent concern. Traditional approaches for predicting SCA, particularly "track-and-trigger" warning systems have demonstrated considerable inadequacies, including low sensitivity, false alarms, decreased diagnostic liability, reliance on clinician involvement, and human errors. Artificial intelligence (AI) and machine learning (ML) models have demonstrated near-perfect accuracy in predicting SCA risk, allowing clinicians to intervene timely. Given the constraints of current diagnostics, exploring the benefits of AI and ML models in enhancing outcomes for SCA/SCD is imperative. This review article aims to investigate the efficacy of AI and ML models in predicting and managing SCD, particularly targeting accuracy in prediction.

How Will Artificial Intelligence Shape the Future of Decision-Making in Congenital Heart Disease?

Improvements in medical technology have significantly changed the management of congenital heart disease (CHD), offering novel tools to predict outcomes and personalize follow-up care. By using sophisticated imaging modalities, computational models and machine learning algorithms, clinicians can experiment with unprecedented insights into the complex anatomy and physiology of CHD. These tools enable early identification of high-risk patients, thus allowing timely, tailored interventions and improved outcomes. Additionally, the integration of genetic testing offers valuable prognostic information, helping in risk stratification and treatment optimisation. The birth of telemedicine platforms and remote monitoring devices facilitates customised follow-up care, enhancing patient engagement and reducing healthcare disparities. Taking into consideration challenges and ethical issues, clinicians can make the most of the full potential of artificial intelligence (AI) to further refine prognostic models, personalize care and improve long-term outcomes for patients with CHD. This narrative review aims to provide a comprehensive illustration of how AI has been implemented as a new technological method for enhancing the management of CHD.

Artificial Intelligence in Cardiology and Atherosclerosis in the Context of Precision Medicine: A Scoping Review

Cardiovascular diseases remain the main cause of death worldwide which makes it essential to better understand, diagnose, and treat atherosclerosis. Artificial intelligence (AI) and novel technological solutions offer us new possibilities and enable the practice of individually tailored medicine. The study was performed using the PRISMA protocol. As of January 10, 2023, the analysis has been based on a review of 457 identified articles in PubMed and MEDLINE databases. The search covered reviews, original articles, meta-analyses, comments, and editorials published in the years 2009-2023. In total, 123 articles met inclusion criteria. The results were divided into the subsections presented in the review (genome-wide association studies, radiomics, and other studies). This paper presents actual knowledge concerning atherosclerosis, in silico, and big data analyses in cardiology that affect the way medicine is practiced in order to create an individual approach and adjust the therapy of atherosclerosis.

Computer-aided analysis of radiological images for cancer diagnosis: performance analysis on benchmark datasets, challenges, and directions

Radiological image analysis using machine learning has been extensively applied to enhance biopsy diagnosis accuracy and assist radiologists with precise cures. With improvements in the medical industry and its technology, computer-aided diagnosis (CAD) systems have been essential in detecting early cancer signs in patients that could not be observed physically, exclusive of introducing errors. CAD is a detection system that combines artificially intelligent techniques with image processing applications thru computer vision. Several manual procedures are reported in state of the art for cancer diagnosis. Still, they are costly, time-consuming and diagnose cancer in late stages such as CT scans, radiography, and MRI scan. In this research, numerous state-of-the-art approaches on multi-organs detection using clinical practices are evaluated, such as cancer, neurological, psychiatric, cardiovascular and abdominal imaging. Additionally, numerous sound approaches are clustered together and their results are assessed and compared on benchmark datasets. Standard metrics such as accuracy, sensitivity, specificity and false-positive rate are employed to check the validity of the current models reported in the literature. Finally, existing issues are highlighted and possible directions for future work are also suggested.

Central stress pathways in the development of cardiovascular disease

PURPOSE

Mental stress is of essential consideration when assessing cardiovascular pathophysiology in all patient populations. Substantial evidence indicates associations among stress, cardiovascular disease and aberrant brain-body communication. However, our understanding of the flow of stress information in humans, is limited, despite the crucial insights this area may offer into future therapeutic targets for clinical intervention.

METHODS

Key terms including mental stress, cardiovascular disease and central control, were searched in PubMed, ScienceDirect and Scopus databases. Articles indicative of heart rate and blood pressure regulation, or central control of cardiovascular disease through direct neural innervation of the cardiac, splanchnic and vascular regions were included. Focus on human neuroimaging research and the flow of stress information is described, before brain-body connectivity, via pre-motor brainstem intermediates is discussed. Lastly, we review current understandings of pathophysiological stress and cardiovascular disease aetiology.

RESULTS

Structural and functional changes to corticolimbic circuitry encode stress information, integrated by the hypothalamus and amygdala. Pre-autonomic brain-body relays to brainstem and spinal cord nuclei establish dysautonomia and lead to alterations in baroreflex functioning, firing of the sympathetic fibres, cellular reuptake of norepinephrine and withdrawal of the parasympathetic reflex. The combined result is profoundly adrenergic and increases the likelihood of cardiac myopathy, arrhythmogenesis, coronary ischaemia, hypertension and the overall risk of future sudden stress-induced heart failure.

CONCLUSIONS

There is undeniable support that mental stress contributes to the development of cardiovascular disease. The emerging accumulation of large-scale multimodal neuroimaging data analytics to assess this relationship promises exciting novel therapeutic targets for future cardiovascular disease detection and prevention.

Artificial Intelligence in Transcatheter Aortic Valve Replacement: Its Current Role and Ongoing Challenges

Transcatheter aortic valve replacement (TAVR) has emerged as a viable alternative to surgical aortic valve replacement, as accumulating clinical evidence has demonstrated its safety and efficacy. TAVR indications have expanded beyond high-risk or inoperable patients to include intermediate and low-risk patients with severe aortic stenosis. Artificial intelligence (AI) is revolutionizing the field of cardiology, aiding in the interpretation of medical imaging and developing risk models for at-risk individuals and those with cardiac disease. This article explores the growing role of AI in TAVR procedures and assesses its potential impact, with particular focus on its ability to improve patient selection, procedural planning, post-implantation monitoring and contribute to optimized patient outcomes. In addition, current challenges and future directions in AI implementation are highlighted.

CARDPSoML: Comparative approach to analyze and predict cardiovascular disease based on medical report data and feature fusion approach

Background and Aims

Diabetes patients are at high risk for cardiovascular disease (CVD), which makes early identification and prompt management essential. To diagnose CVD in diabetic patients, this work attempts to provide a feature-fusion strategy employing supervised learning classifiers.

Methods

Preprocessing patient data is part of the method, and it includes important characteristics connected to diabetes including insulin resistance and blood glucose levels. Principal component analysis and wavelet transformations are two examples of feature extraction techniques that are used to extract pertinent characteristics. The supervised learning classifiers, such as neural networks, decision trees, and support vector machines, are then trained and assessed using these characteristics.

Results

Based on the area under the receiver operating characteristic curve, sensitivity, specificity, and accuracy, these classifiers' performance is closely evaluated. The assessment findings show that the classifiers have a good accuracy and area under the receiver operating characteristic curve value, suggesting that the suggested strategy may be useful in diagnosing CVD in patients with diabetes.

Conclusion

The recommended method shows potential as a useful tool for developing clinical decision support systems and for the early detection of CVD in diabetes patients. To further improve diagnostic skills, future research projects may examine the use of bigger and more varied datasets as well as different machine learning approaches. Using an organized strategy is a crucial first step in tackling the serious problem of CVD in people with diabetes.

Comparison and use of explainable machine learning-based survival models for heart failure patients

Objective

Explainable machine learning (XAI) was introduced in this study to improve the interpretability, explainability and transparency of the modelling results. The survex package in R was used to interpret and compare two survival models - the Cox proportional hazards regression (coxph) model and the random survival forest (rfsrc) model - and to estimate overall survival (OS) and its determinants in heart failure (HF) patients using these models.

Methods

We selected 1159 HF patients hospitalised at the First Affiliated Hospital of Kunming Medical University. First, the performance of the two models was investigated using the C-index, the integrated C/D AUC, and the integrated Brier score. Second, a global explanation of the whole cohort was carried out using the time-dependent variable importance and the partial dependence survival profile. Finally, the SurvSHAP(t) and SurvLIME plots and the ceteris paribus survival profile were used to obtain a local explanation for each patient.

Results

By comparing the C-index, the C/D AUC, and the Brier score, this study showed that the model performance of rfsrc was better than coxph. The global explanation of the whole cohort suggests that the C-reactive protein, lg BNP (brain natriuretic peptide), estimated glomerular filtration rate, albumin, age and blood chloride were significant unfavourable predictors of OS in HF patients in both the cxoph and the rfsrc models. By including individual patients in the model, we can provide a local explanation for each patient, which guides the clinician in individualising the patient's treatment.

Conclusion

By comparison, we conclude that the model performance of rfsrc is better than that of coxph. These two predictive models, which address not only the whole population but also selected patients, can help clinicians personalise the treatment of each HF patient according to his or her specific situation.

Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm: A Review

Cardiovascular disease (CVD) related mortality and morbidity heavily strain society. The relationship between external risk factors and our genetics have not been well established. It is widely acknowledged that environmental influence and individual behaviours play a significant role in CVD vulnerability, leading to the development of polygenic risk scores (PRS). We employed the PRISMA search method to locate pertinent research and literature to extensively review artificial intelligence (AI)-based PRS models for CVD risk prediction. Furthermore, we analyzed and compared conventional vs. AI-based solutions for PRS. We summarized the recent advances in our understanding of the use of AI-based PRS for risk prediction of CVD. Our study proposes three hypotheses: i) Multiple genetic variations and risk factors can be incorporated into AI-based PRS to improve the accuracy of CVD risk predicting. ii) AI-based PRS for CVD circumvents the drawbacks of conventional PRS calculators by incorporating a larger variety of genetic and non-genetic components, allowing for more precise and individualised risk estimations. iii) Using AI approaches, it is possible to significantly reduce the dimensionality of huge genomic datasets, resulting in more accurate and effective disease risk prediction models. Our study highlighted that the AI-PRS model outperformed traditional PRS calculators in predicting CVD risk. Furthermore, using AI-based methods to calculate PRS may increase the precision of risk predictions for CVD and have significant ramifications for individualized prevention and treatment plans.

Mapping the Heartbeat of America with ChatGPT-4: Unpacking the Interplay of Social Vulnerability, Digital Literacy, and Cardiovascular Mortality in County Residency Choices

Cardiovascular disease remains a leading cause of morbidity and mortality in the United States (US). Although high-quality data are accessible in the US for cardiovascular research, digital literacy (DL) has not been explored as a potential factor influencing cardiovascular mortality, although the Social Vulnerability Index (SVI) has been used previously as a variable in predictive modeling. Utilizing a large language model, ChatGPT4, we investigated the variability in CVD-specific mortality that could be explained by DL and SVI using regression modeling. We fitted two models to calculate the crude and adjusted CVD mortality rates. Mortality data using ICD-10 codes were retrieved from CDC WONDER, and the geographic level data was retrieved from the US Department of Agriculture. Both datasets were merged using the Federal Information Processing Standards code. The initial exploration involved data from 1999 through 2020 (n = 65,791; 99.98% complete for all US Counties) for crude cardiovascular mortality (CCM). Age-adjusted cardiovascular mortality (ACM) had data for 2020 (n = 3118 rows; 99% complete for all US Counties), with the inclusion of SVI and DL in the model (a composite of literacy and internet access). By leveraging on the advanced capabilities of ChatGPT4 and linear regression, we successfully highlighted the importance of incorporating the SVI and DL in predicting adjusted cardiovascular mortality. Our findings imply that just incorporating internet availability in the regression model may not be sufficient without incorporating significant variables, such as DL and SVI, to predict ACM. Further, our approach could enable future researchers to consider DL and SVI as key variables to study other health outcomes of public-health importance, which could inform future clinical practices and policies.

Interpretable prediction of 3-year all-cause mortality in patients with chronic heart failure based on machine learning

BACKGROUND

The goal of this study was to assess the effectiveness of machine learning models and create an interpretable machine learning model that adequately explained 3-year all-cause mortality in patients with chronic heart failure.

METHODS

The data in this paper were selected from patients with chronic heart failure who were hospitalized at the First Affiliated Hospital of Kunming Medical University, from 2017 to 2019 with cardiac function class III-IV. The dataset was explored using six different machine learning models, including logistic regression, naive Bayes, random forest classifier, extreme gradient boost, K-nearest neighbor, and decision tree. Finally, interpretable methods based on machine learning, such as SHAP value, permutation importance, and partial dependence plots, were used to estimate the 3-year all-cause mortality risk and produce individual interpretations of the model's conclusions.

RESULT

In this paper, random forest was identified as the optimal aools lgorithm for this dataset. We also incorporated relevant machine learning interpretable tand techniques to improve disease prognosis, including permutation importance, PDP plots and SHAP values for analysis. From this study, we can see that the number of hospitalizations, age, glomerular filtration rate, BNP, NYHA cardiac function classification, lymphocyte absolute value, serum albumin, hemoglobin, total cholesterol, pulmonary artery systolic pressure and so on were important for providing an optimal risk assessment and were important predictive factors of chronic heart failure.

CONCLUSION

The machine learning-based cardiovascular risk models could be used to accurately assess and stratify the 3-year risk of all-cause mortality among CHF patients. Machine learning in combination with permutation importance, PDP plots, and the SHAP value could offer a clear explanation of individual risk prediction and give doctors an intuitive knowledge of the functions of important model components.

Identification of key genes and their correlation with immune infiltration in osteoarthritis using integrative bioinformatics approaches and machine-learning strategies

Osteoarthritis (OA) is a common degenerative joint disease and is closely associated with chronic, low-grade inflammation. Regulating ferroptosis by targeting ferroptosis-related genes may be a fast and effective way to delay the degeneration of OA. However, the molecular mechanisms and gene targets related to ferroptosis in OA are still unclear. Data of OA samples from 3 gene expression omnibus (GEO) datasets were combined to identify differentially expressed genes (DEGs). Ferroptosis-related genes (FRGs) retrieved by the Ferroptosis database were intersected with DEGs, and the intersected hub genes were used for functional enrichment analysis. The feature genes were obtained from the least absolute shrinkage and selection operator (LASSO) algorithm, support vector machine recursive feature elimination (SVM-RFE) algorithm, and random forest (RF) algorithm. Single sample gene set enrichment analysis (ssGSEA) was used to compare immune infiltration between OA patients and normal controls, and the correlation between feature genes and immune cells was analyzed. The expression levels of feature genes were confirmed by RT-PCR. In addition, to explore the applicability of these genes, we extended the bioinformatics analysis of these feature genes to cancer. Finally, 4 feature genes, GABARAPL1, TNFAIP3, ARNTL, and JUN, were confirmed in OA. Theirs expression level were validated by RT-PCR. ROC curves of the 4 genes exhibit excellent diagnostic efficiency for OA, suggesting that the 4 genes were associated with the pathogenesis of OA. Another GEO dataset validated this result. Further analysis revealed that the 4 feature genes were all closely related to the immune infiltration cells in OA. Additionally, results of prognosis analysis indicated that JUN might be a promising therapeutic target for cancer. GABARAPL1, TNFAIP3, ARNTL, and JUN may be predicted biomarkers for OA. The feature genes and association between feature genes and immune infiltration may provide potential biomarkers for OA prediction along with the better assessment of the disease.

Patient-level explainable machine learning to predict major adverse cardiovascular events from SPECT MPI and CCTA imaging

BACKGROUND

Machine learning (ML) has shown promise in improving the risk prediction in non-invasive cardiovascular imaging, including SPECT MPI and coronary CT angiography. However, most algorithms used remain black boxes to clinicians in how they compute their predictions. Furthermore, objective consideration of the multitude of available clinical data, along with the visual and quantitative assessments from CCTA and SPECT, are critical for optimal patient risk stratification. We aim to provide an explainable ML approach to predict MACE using clinical, CCTA, and SPECT data.

METHODS

Consecutive patients who underwent clinically indicated CCTA and SPECT myocardial imaging for suspected CAD were included and followed up for MACEs. A MACE was defined as a composite outcome that included all-cause mortality, myocardial infarction, or late revascularization. We employed an Automated Machine Learning (AutoML) approach to predict MACE using clinical, CCTA, and SPECT data. Various mainstream models with different sets of hyperparameters have been explored, and critical predictors of risk are obtained using explainable techniques on the global and patient levels. Ten-fold cross-validation was used in training and evaluating the AutoML model.

RESULTS

A total of 956 patients were included (mean age 61.1 ±14.2 years, 54% men, 89% hypertension, 81% diabetes, 84% dyslipidemia). Obstructive CAD on CCTA and ischemia on SPECT were observed in 14% of patients, and 11% experienced MACE. ML prediction's sensitivity, specificity, and accuracy in predicting a MACE were 69.61%, 99.77%, and 96.54%, respectively. The top 10 global predictive features included 8 CCTA attributes (segment involvement score, number of vessels with severe plaque ≥70, ≥50% stenosis in the left marginal coronary artery, calcified plaque, ≥50% stenosis in the left circumflex coronary artery, plaque type in the left marginal coronary artery, stenosis degree in the second obtuse marginal of the left circumflex artery, and stenosis category in the marginals of the left circumflex artery) and 2 clinical features (past medical history of MI or left bundle branch block, being an ever smoker).

CONCLUSION

ML can accurately predict risk of developing a MACE in patients suspected of CAD undergoing SPECT MPI and CCTA. ML feature-ranking can also show, at a sample- as well as at a patient-level, which features are key in making such a prediction.

Deep learning for ECG Arrhythmia detection and classification: an overview of progress for period 2017-2023

Cardiovascular diseases are a leading cause of mortality globally. Electrocardiography (ECG) still represents the benchmark approach for identifying cardiac irregularities. Automatic detection of abnormalities from the ECG can aid in the early detection, diagnosis, and prevention of cardiovascular diseases. Deep Learning (DL) architectures have been successfully employed for arrhythmia detection and classification and offered superior performance to traditional shallow Machine Learning (ML) approaches. This survey categorizes and compares the DL architectures used in ECG arrhythmia detection from 2017-2023 that have exhibited superior performance. Different DL models such as Convolutional Neural Networks (CNNs), Multilayer Perceptrons (MLPs), Transformers, and Recurrent Neural Networks (RNNs) are reviewed, and a summary of their effectiveness is provided. This survey provides a comprehensive roadmap to expedite the acclimation process for emerging researchers willing to develop efficient algorithms for detecting ECG anomalies using DL models. Our tailored guidelines bridge the knowledge gap allowing newcomers to align smoothly with the prevailing research trends in ECG arrhythmia detection. We shed light on potential areas for future research and refinement in model development and optimization, intending to stimulate advancement in ECG arrhythmia detection and classification.

Identification of four-gene signature to diagnose osteoarthritis through bioinformatics and machine learning methods

BACKGROUND

Although osteoarthritis (OA) is one of the most prevalent joint disorders, effective biomarkers to diagnose OA are still unavailable. This study aimed to acquire some key synovial biomarkers (hub genes) and analyze their correlation with immune infiltration in OA.

METHODS

Gene expression profiles and clinical characteristics of OA and healthy synovial samples were retrieved from the Gene Expression Omnibus (GEO) database. Hub genes for OA were mined based on a combination of weighted gene co-expression network analysis (WGCNA), the least absolute shrinkage and selection operator (LASSO), support vector machine recursive feature elimination (SVM-RFE), and random forest (RF) algorithms. A diagnostic nomogram model for OA prediction was developed based on the hub genes. Receiver operating characteristic curves (ROC) were performed to confirm the abnormal expression of hub genes in the experimemtal and validation datasets. qRT-PCR using patients' samples were conducted as well. In addition, the infiltration level of 28 immune cells in the expression profile and their relationship with hub genes were analyzed using single-sample GSEA (ssGSEA).

RESULTS

4 hub genes (ZBTB16, TNFSF11, SCRG1 and KDELR3) were obtained by WGCNA, lasso, SVM-RFE, RF algorithms as potential biomarkers for OA. The immune infiltration analyses revealed that hub genes were most correlated with regulatory T cell and natural killer cell.

CONCLUSION

A machine learning model to diagnose OA based on ZBTB16, TNFSF11, SCRG1 and KDELR3 using synovial tissue was constructed, providing theoretical foundation and guideline for diagnostic and treatment targets in OA.

Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach

Introduction: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i), gliflozins, play an emerging role for the treatment of heart failure with reduced left ventricular ejection fraction (HFrEF). Nevertheless, the effects of SGLT2i on ventricular remodeling and function have not been completely understood yet. Explainable artificial intelligence represents an unprecedented explorative option to clinical research in this field. Based on echocardiographic evaluations, we identified some key clinical responses to gliflozins by employing a machine learning approach. Methods: Seventy-eight consecutive diabetic outpatients followed for HFrEF were enrolled in the study. Using a random forests classification, a single subject analysis was performed to define the profile of patients treated with gliflozins. An explainability analysis using Shapley values was used to outline clinical parameters that mostly improved after gliflozin therapy and machine learning runs highlighted specific variables predictive of gliflozin response. Results: The five-fold cross-validation analyses showed that gliflozins patients can be identified with a 0.70 ± 0.03% accuracy. The most relevant parameters distinguishing gliflozins patients were Right Ventricular S'-Velocity, Left Ventricular End Systolic Diameter and E/e' ratio. In addition, low Tricuspid Annular Plane Systolic Excursion values along with high Left Ventricular End Systolic Diameter and End Diastolic Volume values were associated to lower gliflozin efficacy in terms of anti-remodeling effects. Discussion: In conclusion, a machine learning analysis on a population of diabetic patients with HFrEF showed that SGLT2i treatment improved left ventricular remodeling, left ventricular diastolic and biventricular systolic function. This cardiovascular response may be predicted by routine echocardiographic parameters, with an explainable artificial intelligence approach, suggesting a lower efficacy in case of advanced stages of cardiac remodeling.

Machine learning algorithm can provide assistance for the diagnosis of non-ST-segment elevation myocardial infarction

INTRODUCTION

Our aim was to use the constructed machine learning (ML) models as auxiliary diagnostic tools to improve the diagnostic accuracy of non-ST-elevation myocardial infarction (NSTEMI).

MATERIALS AND METHODS

A total of 2878 patients were included in this retrospective study, including 1409 patients with NSTEMI and 1469 patients with unstable angina pectoris. The clinical and biochemical characteristics of the patients were used to construct the initial attribute set. SelectKBest algorithm was used to determine the most important features. A feature engineering method was applied to create new features correlated strongly to train ML models and obtain promising results. Based on the experimental dataset, the ML models of extreme gradient boosting, support vector machine, random forest, naïve Bayesian, gradient boosting machines and logistic regression were constructed. Each model was verified by test set data, and the diagnostic performance of each model was comprehensively evaluated.

RESULTS

The six ML models based on the training set all play an auxiliary role in the diagnosis of NSTEMI. Although all models taken for comparison performed differences, the extreme gradient boosting ML model performed the best in terms of accuracy rate (0.95±0.014), precision rate (0.94±0.011), recall rate (0.98±0.003) and F-1 score (0.96±0.007) in NSTEMI.

CONCLUSIONS

The ML model constructed based on clinical data can be used as an auxiliary tool to improve the accuracy of NSTEMI diagnosis. According to our comprehensive evaluation, the performance of the extreme gradient boosting model was the best.

Artificial Intelligence Technologies in Cardiology

As the world produces exabytes of data, there is a growing need to find new methods that are more suitable for dealing with complex datasets. Artificial intelligence (AI) has significant potential to impact the healthcare industry, which is already on the road to change with the digital transformation of vast quantities of information. The implementation of AI has already achieved success in the domains of molecular chemistry and drug discoveries. The reduction in costs and in the time needed for experiments to predict the pharmacological activities of new molecules is a milestone in science. These successful applications of AI algorithms provide hope for a revolution in healthcare systems. A significant part of artificial intelligence is machine learning (ML), of which there are three main types-supervised learning, unsupervised learning, and reinforcement learning. In this review, the full scope of the AI workflow is presented, with explanations of the most-often-used ML algorithms and descriptions of performance metrics for both regression and classification. A brief introduction to explainable artificial intelligence (XAI) is provided, with examples of technologies that have developed for XAI. We review important AI implementations in cardiology for supervised, unsupervised, and reinforcement learning and natural language processing, emphasizing the used algorithm. Finally, we discuss the need to establish legal, ethical, and methodical requirements for the deployment of AI models in medicine.

Applications of artificial intelligence for patients with peripheral artery disease

OBJECTIVE

Applications of artificial intelligence (AI) have been reported in several cardiovascular diseases but its interest in patients with peripheral artery disease (PAD) has been so far less reported. The aim of this review was to summarize current knowledge on applications of AI in patients with PAD, to discuss current limits, and highlight perspectives in the field.

METHODS

We performed a narrative review based on studies reporting applications of AI in patients with PAD. The MEDLINE database was independently searched by two authors using a combination of keywords to identify studies published between January 1995 and December 2021. Three main fields of AI were investigated including natural language processing (NLP), computer vision and machine learning (ML).

RESULTS

NLP and ML brought new tools to improve the screening, the diagnosis and classification of the severity of PAD. ML was also used to develop predictive models to better assess the prognosis of patients and develop real-time prediction models to support clinical decision-making. Studies related to computer vision mainly aimed at creating automatic detection and characterization of arterial lesions based on Doppler ultrasound examination or computed tomography angiography. Such tools could help to improve screening programs, enhance diagnosis, facilitate presurgical planning, and improve clinical workflow.

CONCLUSIONS

AI offers various applications to support and likely improve the management of patients with PAD. Further research efforts are needed to validate such applications and investigate their accuracy and safety in large multinational cohorts before their implementation in daily clinical practice.

Machine Learning in Cardiology: A Potential Real-World Solution in Low- and Middle-Income Countries

Artificial intelligence (AI) and machine learning (ML) is a promising field of cardiovascular medicine. Many AI tools have been shown to be efficacious with a high level of accuracy. Yet, their use in real life is not well established. In the era of health technology and data science, it is crucial to consider how these tools could improve healthcare delivery. This is particularly important in countries with limited resources, such as low- and middle-income countries (LMICs). LMICs have many barriers in the care continuum of cardiovascular diseases (CVD), and big portion of these barriers come from scarcity of resources, mainly financial and human power constraints. AI/ML could potentially improve healthcare delivery if appropriately applied in these countries. Expectedly, the current literature lacks original articles about AI/ML originating from these countries. It is important to start early with a stepwise approach to understand the obstacles these countries face in order to develop AI/ML-based solutions. This could be detrimental to many patients' lives, in addition to other expected advantages in other sectors, including the economy sector. In this report, we aim to review what is known about AI/ML in cardiovascular medicine, and to discuss how it could benefit LMICs.

Artificial Intelligence for Detection of Dementia Using Motion Data: A Scoping Review

Background

Dementia is a neurodegenerative disease resulting in the loss of cognitive and psychological functions. Artificial intelligence (AI) may help in detection and screening of dementia; however, little is known in this area.

Objectives

The objective of this study was to identify and evaluate AI interventions for detection of dementia using motion data.

Method

The review followed the framework proposed by O'Malley's and Joanna Briggs Institute methodological guidance for scoping reviews. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist for reporting the results. An information specialist performed a comprehensive search from the date of inception until November 2020, in five bibliographic databases: MEDLINE, EMBASE, Web of Science Core Collection, CINAHL, and IEEE Xplore. We included studies aimed at the deployment and testing or implementation of AI interventions using motion data for the detection of dementia among a diverse population, encompassing varying age, sex, gender, economic backgrounds, and ethnicity, extending to their health care providers across multiple health care settings. Studies were excluded if they focused on Parkinson's or Huntington's disease. Two independent reviewers screened the abstracts, titles, and then read the full-texts. Disagreements were resolved by consensus, and if this was not possible, the opinion of a third reviewer was sought. The reference lists of included studies were also screened.

Results

After removing duplicates, 2,632 articles were obtained. After title and abstract screening and full-text screening, 839 articles were considered for categorization. The authors categorized the papers into six categories, and data extraction and synthesis was performed on 20 included papers from the motion tracking data category. The included studies assessed cognitive performance (n = 5, 25%); screened dementia and cognitive decline (n = 8, 40%); investigated visual behaviours (n = 4, 20%); and analyzed motor behaviors (n = 3, 15%).

Conclusions

We presented evidence of AI systems being employed in the detection of dementia, showcasing the promising potential of motion tracking within this domain. Although some progress has been made in this field recently, there remain notable research gaps that require further exploration and investigation. Future endeavors need to compare AI interventions using motion data with traditional screening methods or other tech-enabled dementia detection mechanisms. Besides, future works should aim at understanding how gender and sex, and ethnic and cultural sensitivity can contribute to refining AI interventions, ensuring they are accessible, equitable, and beneficial across all society.

Artificial Intelligence in Pediatric Cardiology: A Scoping Review

The evolution of AI and data science has aided in mechanizing several aspects of medical care requiring critical thinking: diagnosis, risk stratification, and management, thus mitigating the burden of physicians and reducing the likelihood of human error. AI modalities have expanded feet to the specialty of pediatric cardiology as well. We conducted a scoping review searching the Scopus, Embase, and PubMed databases covering the recent literature between 2002-2022. We found that the use of neural networks and machine learning has significantly improved the diagnostic value of cardiac magnetic resonance imaging, echocardiograms, computer tomography scans, and electrocardiographs, thus augmenting the clinicians' diagnostic accuracy of pediatric heart diseases. The use of AI-based prediction algorithms in pediatric cardiac surgeries improves postoperative outcomes and prognosis to a great extent. Risk stratification and the prediction of treatment outcomes are feasible using the key clinical findings of each CHD with appropriate computational algorithms. Notably, AI can revolutionize prenatal prediction as well as the diagnosis of CHD using the EMR (electronic medical records) data on maternal risk factors. The use of AI in the diagnostics, risk stratification, and management of CHD in the near future is a promising possibility with current advancements in machine learning and neural networks. However, the challenges posed by the dearth of appropriate algorithms and their nascent nature, limited physician training, fear of over-mechanization, and apprehension of missing the 'human touch' limit the acceptability. Still, AI proposes to aid the clinician tomorrow with precision cardiology, paving a way for extremely efficient human-error-free health care.

Left Ventricular Diastolic Dysfunction Screening by a Smartphone-Case Based on Single Lead ECG

Aims

To investigate the potential of a signal processed by smartphone-case based on single lead electrocardiogram (ECG) for left ventricular diastolic dysfunction (LVDD) determination as a screening method.

Methods and Results

We included 446 subjects for sample learning and 259 patients for sample test aged 39 to 74 years for testing with 2D-echocardiography, tissue Doppler imaging and ECG using a smartphone-case based single lead ECG monitor for the assessment of LVDD. Spectral analysis of ECG signals (spECG) has been used in combination with advanced signal processing and artificial intelligence methods. Wavelengths slope, time intervals between waves, amplitudes at different points of the ECG complexes, energy of the ECG signal and asymmetry indices were analyzed. The QTc interval indicated significant diastolic dysfunction with a sensitivity of 78% and a specificity of 65%, a Tpeak parameter >590 ms with 63% and 58%, a T value off >695 ms with 63% and 74%, and QRSfi > 674 ms with 74% and 57%, respectively. A combination of the threshold values from all 4 parameters increased sensitivity to 86% and specificity to 70%, respectively (OR 11.7 [2.7-50.9], P < .001). Algorithm approbation have shown: Sensitivity-95.6%, Specificity-97.7%, Diagnostic accuracy-96.5% and Repeatability-98.8%.

Conclusion

Our results indicate a great potential of a smartphone-case based on single lead ECG as novel screening tool for LVDD if spECG is used in combination with advanced signal processing and machine learning technologies.

Scoping review of the current landscape of AI-based applications in clinical trials

Background

Clinical trials are essential for bringing new drugs, technologies and procedures to the market and clinical practice. Considering the design and the four-phase development, only 10% of them complete the entire process, partly due to the increasing costs and complexity of clinical trials. This low completion rate has a huge negative impact in terms of population health, quality of care and health economics and sustainability. Automating some of the process' tasks with artificial intelligence (AI) tools could optimize some of the most burdensome ones, like patient selection, matching and enrollment; better patient selection could also reduce harmful treatment side effects. Although the pharmaceutical industry is embracing artificial AI tools, there is little evidence in the literature of their application in clinical trials.

Methods

To address this issue, we performed a scoping review. Following the PRISMA-ScR guidelines, we performed a search on PubMed for articles on the implementation of AI in the development of clinical trials.

Results

The search yielded 772 articles, of which 15 were included. The articles were published between 2019 and 2022 and the results were presented descriptively. About half of the studies addressed the topic of patient recruitment; 12 articles reported specific examples of AI applications; five studies presented a quantitative estimate of the effectiveness of these tools.

Conclusion

All studies present encouraging results on the implementation of AI-based applications to the development of clinical trials. AI-based applications have a lot of potential, but more studies are needed to validate these tools and facilitate their adoption.

Artificial Intelligence Advances in the World of Cardiovascular Imaging

The tremendous advances in digital information and communication technology have entered everything from our daily lives to the most intricate aspects of medical and surgical care. These advances are seen in electronic and mobile health and allow many new applications to further improve and make the diagnoses of patient diseases and conditions more precise. In the area of digital radiology with respect to diagnostics, the use of advanced imaging tools and techniques is now at the center of evaluation and treatment. Digital acquisition and analysis are central to diagnostic capabilities, especially in the field of cardiovascular imaging. Furthermore, the introduction of artificial intelligence (AI) into the world of digital cardiovascular imaging greatly broadens the capabilities of the field both with respect to advancement as well as with respect to complete and accurate diagnosis of cardiovascular conditions. The application of AI in recognition, diagnostics, protocol automation, and quality control for the analysis of cardiovascular imaging modalities such as echocardiography, nuclear cardiac imaging, cardiovascular computed tomography, cardiovascular magnetic resonance imaging, and other imaging, is a major advance that is improving rapidly and continuously. We document the innovations in the field of cardiovascular imaging that have been brought about by the acceptance and implementation of AI in relation to healthcare professionals and patients in the cardiovascular field.

Applications of Artificial Intelligence in Non-cardiac Vascular Diseases: A Bibliographic Analysis

Research output related to artificial intelligence (AI) in vascular diseases has been poorly investigated. The aim of this study was to evaluate scientific publications on AI in non-cardiac vascular diseases. A systematic literature search was conducted using the PubMed database and a combination of keywords and focused on three main vascular diseases (carotid, aortic and peripheral artery diseases). Original articles written in English and published between January 1995 and December 2020 were included. Data extracted included the date of publication, the journal, the identity, number, affiliated country of authors, the topics of research, and the fields of AI. Among 171 articles included, the three most productive countries were USA, China, and United Kingdom. The fields developed within AI included: machine learning (n = 90; 45.0%), vision (n = 45; 22.5%), robotics (n = 42; 21.0%), expert system (n = 15; 7.5%), and natural language processing (n = 8; 4.0%). The applications were mainly new tools for: the treatment (n = 52; 29.1%), prognosis (n = 45; 25.1%), the diagnosis and classification of vascular diseases (n = 38; 21.2%), and imaging segmentation (n = 38; 21.2%). By identifying the main techniques and applications, this study also pointed to the current limitations and may help to better foresee future applications for clinical practice.

Application of Extreme Learning Machine in the Survival Analysis of Chronic Heart Failure Patients With High Percentage of Censored Survival Time

Objective: To explore the application of the Cox model based on extreme learning machine in the survival analysis of patients with chronic heart failure.

Methods: The medical records of 5,279 inpatients diagnosed with chronic heart failure in two grade 3 and first-class hospitals in Taiyuan from 2014 to 2019 were collected; with death as the outcome and after the feature selection, the Lasso Cox, random survival forest (RSF), and the Cox model based on extreme learning machine (ELM Cox) were constructed for survival analysis and prediction; the prediction performance of the three models was explored based on simulated data with three censoring ratios of 25, 50, and 75%.

Results: Simulation results showed that the prediction performance of the three models decreased with increasing censoring proportion, and the ELM Cox model performed best overall; the ELM Cox model constructed with 21 highly influential survival predictors screened from actual chronic heart failure data showed the best performance with C-index and Integrated Brier Score (IBS) of 0.775(0.755, 0.802) and 0.166(0.150, 0.182), respectively.

Conclusion: The ELM Cox model showed good discrimination performance in the survival analysis of patients with chronic heart failure; it performs consistently for data with a high proportion of censored survival time; therefore, the model could help physicians identify patients at high risk of poor prognosis and target therapeutic measures to patients as early as possible.